Establishment Labs (ESTA) Stock Price, News & Analysis

Company Overview

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

Key Stats

• Today's Range: $41.46 to $42.79
• 50-Day Range: $33.62 to $46.11
• 52-Week Range: $26.56 to $50.85
• Volume: 261,793 shs
• Average Volume: 495,107 shs
• Market Capitalization: $1.23 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $56.50
• Consensus Rating: Moderate Buy

Establishment Labs Stock Analysis - MarketRank™

Establishment Labs scored higher than 37% of companies evaluated by MarketBeat, and ranked 747th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Establishment Labs has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Establishment Labs has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Establishment Labs are expected to grow in the coming year, from ($2.41) to ($1.83) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Establishment Labs is -13.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Establishment Labs is -13.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Establishment Labs has a P/B Ratio of 53.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.48% of the float of Establishment Labs has been sold short.

Short Interest Ratio / Days to Cover

Establishment Labs has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Establishment Labs has recently increased by 1.93%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Establishment Labs does not currently pay a dividend.

Dividend Growth

Establishment Labs does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

18.48% of the float of Establishment Labs has been sold short.

Short Interest Ratio / Days to Cover

Establishment Labs has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Establishment Labs has recently increased by 1.93%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.59

News Sentiment

Establishment Labs has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Establishment Labs this week, compared to 4 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Establishment Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.09% of the stock of Establishment Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

72.91% of the stock of Establishment Labs is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ESTA Stock Analysis - Frequently Asked Questions

How have ESTA shares performed this year?

Establishment Labs' stock was trading at $46.07 at the start of the year. Since then, ESTA stock has decreased by 7.9% and is now trading at $42.44.

How were Establishment Labs' earnings last quarter?

Establishment Labs Holdings Inc. (NASDAQ:ESTA) issued its quarterly earnings data on Thursday, August, 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by $0.03. The business's revenue for the quarter was up 16.1% compared to the same quarter last year.
Read the conference call transcript.

When did Establishment Labs IPO?

Establishment Labs (ESTA) raised $50 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 3,100,000 shares at a price of $15.00-$17.00 per share. Jefferies and Cowen served as the underwriters for the IPO and BTIG was co-manager.

Who are Establishment Labs' major shareholders?

Top institutional investors of Establishment Labs include Brown Advisory Inc. (7.40%), Nantahala Capital Management LLC (6.13%), Tyro Capital Management LLC (3.69%) and Bamco Inc. NY (3.13%). Insiders that own company stock include Nicholas Sheridan Lewin, Quiros Juan Jose Chacon, Raj Denhoy, Raj Denhoy and Leslie Gillin.
View institutional ownership trends.

How do I buy shares of Establishment Labs?

Shares of ESTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Establishment Labs own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Establishment Labs investors own include PayPal (PYPL), NVIDIA (NVDA), Walt Disney (DIS), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD) and Intel (INTC).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 8/28/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:ESTA
• CIK: 1688757
• Web: www.establishmentlabs.com
• Phone: (062) 434-2400
• Fax: N/A
• Employees: 1,018
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Establishment Labs: $56.50
• High Price Target: $70.00
• Low Price Target: $47.00
• Potential Upside/Downside: +33.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$84.60 million
• Net Margins: -49.89%
• Pretax Margin: -49.32%
• Return on Equity: -224.34%
• Return on Assets: -25.53%

Debt

• Debt-to-Equity Ratio: 9.71
• Current Ratio: 2.84
• Quick Ratio: 1.67

Sales & Book Value

• Annual Sales: $166.02 million
• Price / Sales: 7.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.79 per share
• Price / Book: 53.72

Miscellaneous

• Outstanding Shares: 28,970,000
• Free Float: 25,758,000
• Market Cap: $1.23 billion
• Optionable: Optionable
• Beta: 0.83